title: Plasma kallistatin levels in patients with severe community-acquired pneumonia.
abstract: BACKGROUND
  Community-acquired pneumonia (CAP) requiring intensive care unit (ICU) treatment commonly causes acute respiratory failure with high mortality. Kallistatin, an endogenous tissue kallikrein inhibitor, has been reported to be protective in various human diseases. The aim of this study was to assess the correlations of kallistatin with other biomarkers and to determine whether kallistatin levels have a prognostic value in severe CAP.
  
  
  METHODS
  Plasma samples and clinical data were prospectively collected from 54 patients with severe CAP requiring ICU admission. Seventeen healthy control subjects were included for comparison. Plasma kallistatin, kallikrein, and other biomarkers of inflammation (tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, IL-8, C-reactive protein (CRP)), and anti-coagulation (protein C, anti-thrombin III) were measured on days 1 and 4 of ICU admission. Comparison between survivors (n = 41) and nonsurvivors (n = 13) was performed.
  
  
  RESULTS
  Plasma kallistatin was significantly consumed in severe CAP patients compared with healthy individuals. Lower day 1 kallistatin levels showed a strong trend toward increased mortality (P = 0.018) and higher day 1 CURB-65 scores (P = 0.004). Plasma kallistatin levels on day 1 of ICU admission were significantly decreased in patients who developed septic shock (P = 0.017) and who had acute respiratory distress syndrome (P = 0.044). In addition, kallistatin levels were positively correlated with anti-thrombin III and protein C and inversely correlated with IL-1β, IL-6, and CRP levels. In a multivariate logistic regression analysis, higher day 1 CURB-65 scores were independent predictors of mortality (odds ratio = 29.9; P = 0.009). Also, higher day 1 kallistatin levels were independently associated with a decreased risk of death (odds ratio, 0.1) with a nearly significant statistical difference (P = 0.056). Furthermore, we found that a cutoff level of 6.5 μg/ml of day 1 kallistatin determined by receiver operating characteristic curves could be used to distinguish between patients who survived in 60 days and those who did not.
  
  
  CONCLUSIONS
  These results suggest that kallistatin may serve as a novel marker for severe CAP prognosis and may be involved in the pathogenesis of CAP through antiinflammatory and anticoagulation effects.
authors: Wei-Chieh
authors: WC
authors: Lin
authors: Shiou-Ling
authors: SL
authors: Lu
authors: Chiou-Feng
authors: CF
authors: Lin
authors: Chang-Wen
authors: CW
authors: Chen
authors: Lee
authors: L
authors: Chao
authors: Julie
authors: J
authors: Chao
authors: Yee-Shin
authors: YS
authors: Lin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D017714:Community-Acquired Infections / Q000097:blood / Q000175:diagnosis / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D011014:Pneumonia / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D011446:Prospective Studies; D015843:Serpins / Q000097:blood*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D015415:Biomarkers; D015843:Serpins; C051324:kallistatin
references: Hypertension. 2008 May;51(5):1358-65
references: 18391098
references: Crit Care. 2012 Dec 12;16(2):R53
references: 22449513
references: World J Gastroenterol. 2011 Jan 7;17(1):111-7
references: 21218091
references: Ann Emerg Med. 2008 Jul;52(1):48-58.e2
references: 18342993
references: J Biol Chem. 1992 Dec 25;267(36):25873-80
references: 1334488
references: J Crit Care. 2011 Jun;26(3):287-94
references: 21129911
references: Crit Care Med. 1985 Oct;13(10):818-29
references: 3928249
references: J Histochem Cytochem. 1999 Feb;47(2):221-8
references: 9889257
references: J Lab Clin Med. 1996 Jun;127(6):612-20
references: 8648266
references: Crit Care Med. 2005 Feb;33(2):341-8
references: 15699837
references: Lab Invest. 2008 Nov;88(11):1157-66
references: 18762777
references: Intensive Care Med. 1996 Jul;22(7):707-10
references: 8844239
references: Hum Gene Ther. 2006 Dec;17(12):1201-13
references: 17081080
references: Crit Care Med. 2011 Oct;39(10):2211-7
references: 21705887
references: Thorax. 2007 Mar;62(3):253-9
references: 16928720
references: Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54
references: 11401897
references: Blood. 2002 Nov 1;100(9):3245-52
references: 12384424
references: Thorax. 2009 Jul;64(7):587-91
references: 19131448
references: Thorax. 2003 May;58(5):377-82
references: 12728155
references: J Mol Med (Berl). 2010 Feb;88(2):121-6
references: 20232512
references: Pancreas. 1999 Nov;19(4):325-34
references: 10547191
references: Ann Emerg Med. 2009 May;53(5):633-8
references: 19201061
references: Arthritis Rheum. 2005 Apr;52(4):1319-24
references: 15818689
references: Eur Respir J. 2008 Feb;31(2):349-55
references: 17959641
references: Hum Gene Ther. 2009 Feb;20(2):147-58
references: 20377366
references: Respirology. 2010 Jul;15(5):796-803
references: 20497384
references: Life Sci. 1997;60(17):1431-5
references: 9126863
references: Chest. 2008 Mar;133(3):610-7
references: 17989157
references: Crit Care. 2011;15(2):R88
references: 21385367
references: Mol Med. 2009 Nov-Dec;15(11-12):438-45
references: 19753144